Aethlon Medical Inc (AEMD) Stock Price & Analysis

Aethlon Medical Inc (AEMD) fell 5.70% to USD 1.82 as of September 8, 2026 at 09:02 UTC, according to Nexqual real-time market data.

AEMD last closed at USD 1.82; the session ranged USD 1.7–1.82 on volume of 165,472 shares. Market capitalization is —, with a 52-week range of USD 1.67–41.5 (NCM). Source: Nexqual, September 8, 2026 at 09:02 UTC.

Key Statistics (as of September 8, 2026 at 09:02 UTC)

Technical Analysis (AEMD)

Nexqual's technical model rates AEMD "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:02 UTC.

From Aethlon Medical Inc's Latest SEC 10-K Filing (filed 2026-06-10)

Key Strengths & Strategy (as disclosed to the SEC)

• Following the filing of the amendment, the Company may offer and sell shares of its common stock having an aggregate offering price of up to approximately $542,716 pursuant to its ATM facility.   Intellectual Property   We rely on a combination of patents, trade secrets, know-how, trademarks, and confidentiality agreements to protect our proprietary technologies, including the Hemopurifier platform.
• Our patent portfolio relates primarily to extracorporeal removal technologies, viral and exosome-related applications, and related therapeutic methods.   We also maintain trademark registrations for Hemopurifier and Aethlon Medical in the United States, trademark protection for Hemopurifier in India, and international trademark protection for SANSAGITTA in multiple jurisdictions, including Australia, Canada, the European Union, the United Kingdom, and India.
• In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation, or QSR.

Partnerships

• Payors may include the Centers for Medicare & Medicaid Services, or CMS, which administers the Medicare program and works in partnership with state governments to administer Medicaid, other government programs and private insurance plans.
• Therefore, coverage and reimbursement can differ significantly from payor to payor.   Manufacturing   Historically, manufacturing of our Hemopurifier was conducted in collaboration with a contract manufacturer based in California, operating under current Good Manufacturing Practice, or cGMP, regulations promulgated by the FDA. Our contract manufacturer is registered with the FDA.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:02 UTC. This page is informational and not investment advice.